Eisai (ESALY) News Today

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

$61.51

-1.33 (-2.11%)

(As of 01/30/2023)

Stock Analysis

Source

Source	Headline
	Eisai (OTCMKTS:ESALY) Stock Price Crosses Below 50-Day Moving Average of $61.51 americanbankingnews.com - April 13 at 4:56 AM
	Eisai Co. Ltd. ADR wsj.com - March 29 at 2:24 PM
	Eisai Co Ltd reuters.com - March 23 at 5:55 AM
	Eisai Co Ltd 4523 morningstar.com - March 20 at 6:28 PM
	BIIB Mar 2024 210.000 call finance.yahoo.com - February 15 at 3:15 PM
	BIIB Feb 2024 227.500 call finance.yahoo.com - February 15 at 10:15 AM
	BIIB Mar 2024 235.000 call finance.yahoo.com - February 15 at 10:15 AM
	BIIB Mar 2024 205.000 put finance.yahoo.com - February 14 at 11:54 PM
	ESALF Eisai Co., Ltd. seekingalpha.com - January 12 at 6:27 PM
	Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints markets.businessinsider.com - December 8 at 7:55 AM
	Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi msn.com - September 25 at 3:59 PM
	Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer msn.com - September 22 at 12:33 PM
	Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi (ESALY) marketbeat.com - July 10 at 7:10 AM
	FDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's Disease markets.businessinsider.com - July 6 at 11:16 PM
	Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources benzinga.com - June 13 at 3:48 PM
	FDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug Leqembi markets.businessinsider.com - June 11 at 11:48 PM
	Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' msn.com - June 8 at 1:39 PM
	UTHR or ESALY: Which Is the Better Value Stock Right Now? finance.yahoo.com - January 9 at 5:01 PM
	FDA approves treatment for people with mild forms of Alzheimer’s finance.yahoo.com - January 6 at 3:34 PM
	Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate finance.yahoo.com - November 30 at 7:25 PM
	Biogen rallies Alzheimer’s drug developers after full data for lecanemab seekingalpha.com - November 30 at 2:24 PM
	Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's finance.yahoo.com - November 30 at 2:24 PM
	Biogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swelling seekingalpha.com - November 30 at 9:24 AM
	Biogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom. barrons.com - November 30 at 9:24 AM
	Biogen drops after report on second death linked to Alzheimer’s candidate seekingalpha.com - November 28 at 4:38 PM
	UTHR vs. ESALY: Which Stock Is the Better Value Option? finance.yahoo.com - November 28 at 4:38 PM
	After Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy? msn.com - November 17 at 4:23 AM
	Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers finance.yahoo.com - November 15 at 3:45 AM
	FY2024 Earnings Estimate for Eisai Co., Ltd. (OTCMKTS:ESALY) Issued By Jefferies Financial Group marketbeat.com - November 2 at 8:18 AM
	Patient Death in Alzheimer's Study May Limit Drug's Reach msn.com - October 29 at 7:50 PM
	Biogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executive seekingalpha.com - October 18 at 6:22 PM
	Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers finance.yahoo.com - October 18 at 3:11 AM
	Biogen shares soar on landmark Alzheimer's data, lift rivals investing.com - September 29 at 1:06 PM
	Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data seekingalpha.com - September 28 at 8:58 PM
	This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval finance.yahoo.com - September 28 at 3:58 PM
	2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data markets.businessinsider.com - September 28 at 10:57 AM
	Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly investing.com - September 28 at 10:57 AM
	Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial seekingalpha.com - September 28 at 10:57 AM
	Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game realmoney.thestreet.com - September 28 at 10:57 AM
	Is This the First Alzheimer's Drug to Actually Work? msn.com - September 28 at 10:57 AM
	Eisai says Alzheimer's drug succeeds in slowing cognitive decline investing.com - September 28 at 1:17 AM
	Biogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trial seekingalpha.com - September 28 at 1:17 AM
	Pharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug Trial barrons.com - September 27 at 8:17 PM
	Eisai Co., Ltd (ADR) (OTC: ESALY) fool.com - September 24 at 10:57 PM
	Can We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues. barrons.com - September 23 at 11:50 AM
	ESALY Eisai Co., Ltd. seekingalpha.com - September 18 at 12:28 AM
	Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer finance.yahoo.com - September 12 at 9:56 AM
	Eisai Co., Ltd. (4523) investing.com - August 16 at 9:22 PM
	Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript seekingalpha.com - August 6 at 3:05 PM
	Eisai is about to announce its earnings — here's what to expect markets.businessinsider.com - August 6 at 12:03 AM

Get Eisai News Delivered to You Automatically

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

ESALY Media Mentions By Week

ESALY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ESALY
News Sentiment
▼
0.00

0.52
▲
Average
Medical
News Sentiment

ESALY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ESALY Articles
This Week
▼
1

0
▲
ESALY Articles
Average Week

Get Eisai News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (OTCMKTS:ESALY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eisai (ESALY) News Today

ESALY Media Mentions By Week

ESALY Media Sentiment

ESALY News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info